血脂康预防非药物涂层支架治疗术后再狭窄的临床研究(3)
 |
| 第1页 |
参见附件(325KB，3页)。
3 Li C, Yang CW, Park JH, et al.Pravastatin treatment attenuates interstitial inflammation and fibrosis in a rat model of chroniccyclosporineinduced nephropathy. Am J Physiol Renal Physiol,2004, 286(1): 46-57.
4 Chauhan NB, Siegel GJ, Feinstein DL. Effects of lovastatin and pravastatin on amyloid processing and inflammatory response in TgCRND8 BRAIN J Neuro Chem. Res 2004,29(10):1897-1911.
5 Girman CJ, Rhodes T, Mercuri M, et al. The metabolic syndrome and risk of major coronary events in the scandinavian simvastatin surviv al study (4 s) and the air force/texas coronary atherosclerosis prevention study (AFCAPA/TexCAPS).Am J Cardiol, 2004, 93(2): 136-141.
6 Pyorala K, Ballantyne C, Lee M,et al.Reduction of cornonary events by simvastatin in non diabetic coronary heart disease patients with and without the metabolic syndrome: subgroup analysis of the scan dianvian simvastatin survival study (4s).Diabetes, 2003, 52(1): 19.
7 Ling L, Shui-Ping Z, Yan-Chun C, et al. Xuezhikang decreases serum lipoprotein(a) and C-reactive Protein concentrations in patients with coronary heart disease. Clinical Chemistry,2003,49(8):1347-1352.
8 Jian-Jun L, Sheng-Shou H, Chun-Hong F, et al. Effects of Xuezhikang, an extract of cholestin, on lipid profile and C-reactive protein: a short-term time course study in patients with stable angina. Clinica Chimica Acta,2005,352:217-224.
9 Shui-Ping Z, Ling L, Yan-Chun C, et al. Xuezhikang, an extract of cholestin, protects endothelial function through antiinflammatoryand Lipid-Lowering mechanisms in patients with coronary heart disease .Circulation,2004,110:915-920.
10 Schwartz RS. Pathophysiology of restenosis: interaction of thrombosis, hyperplasis and/or remodeling.Am J Cardiol,1998,81(7):14-17.
“本文中所涉及到的图表、注解、公式等内容请以PDF格式阅读原文”。
您现在查看是摘要介绍页，详见PDF附件(325KB，3页)。